{"id":"W3024013989","doi":"10.1093/ehjqcco/qcaa045","title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","year":2020,"lang":"en","type":"article","venue":"European Heart Journal - Quality of Care and Clinical Outcomes","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":86,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Institut universitaire de cardiologie et de pneumologie de Québec; Université de Montréal; Université Laval; Cegep regional de Lanaudiere; Montreal Heart Institute","funders":"Medical Research Council; Canadian Institutes of Health Research; Abbott Vascular; Esperion Therapeutics; School of Medicine, New York University; Institut de Cardiologie de Montréal; Duke Clinical Research Institute; Eisai; Bausch Health; Heart Research Institute; University of Glasgow; Medicines Company; AstraZeneca; Amarin Corporation; Singulex; Ionis Pharmaceuticals; TG Therapeutics; Boston Scientific Corporation; McMaster University; Daiichi Sankyo Europe; Servier; Gilead Sciences; Kowa Company; Sanofi; Celgene; York University; Pfizer; Biogen; HLS Therapeutics; GlaxoSmithKline; Amgen; Vifor Pharma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Myocardial infarction; Clinical endpoint; Placebo; Quality-adjusted life year; Internal medicine; Cost effectiveness; Randomized controlled trial; Colchicine; Emergency medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001621193,0.0006461309,0.001205867,0.0002169479,0.0001844694,0.0008218873,0.0004921645,0.0007811524,0.002473089],"category_scores_gemma":[0.003978705,0.0001895852,0.001664686,0.0003022418,0.0002890644,0.0003680254,0.0003865724,0.001214418,0.000096857],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002169515,"about_ca_system_score_gemma":0.001731914,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01321679,"about_ca_topic_score_gemma":0.02078702,"domain_scores_codex":[0.9991508,0.0006278325,0.00003040952,0.00007160082,0.00005058173,0.00006880696],"domain_scores_gemma":[0.9989499,0.000553065,0.0002622962,0.0000279781,0.00005047747,0.0001562184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7551642,0.004791331,0.04386874,0.005464938,0.01715452,0.0003370894,0.000107314,0.05866073,0.002171095,0.002303329,0.008476315,0.1015004],"study_design_scores_gemma":[0.5383801,0.09305438,0.1396023,0.001673028,0.03235053,0.0006324849,0.0002004149,0.1793302,0.002120283,0.005749112,0.006721547,0.0001856158],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9713809,0.01715007,0.001789118,0.002265108,0.0002558915,0.0008592053,0.003342298,0.00009482011,0.002862543],"genre_scores_gemma":[0.9955172,0.001644539,0.0006516068,0.0002503527,0.00004897436,0.0002268641,0.001310305,0.000004210099,0.0003458808],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01321679,"threshold_uncertainty_score":0.02627975,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09466913813290288,"score_gpt":0.4031583504076356,"score_spread":0.3084892122747327,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}